Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TERENCE ISAKOV

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497729222
CMS profile
339847
Location
LYNDHURST, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,435.31

79 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,435.31 79

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TERENCE ISAKOV

NPI 1497729222 · CMS profile ID 339847

Allopathic & Osteopathic Physicians / Family Medicine

LYNDHURST, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497729222?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TERENCE ISAKOV, NPI 1497729222, CMS profile ID 339847. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497729222?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TERENCE ISAKOV, NPI 1497729222, CMS profile ID 339847. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497729222?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TERENCE ISAKOV, NPI 1497729222, CMS profile ID 339847, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 79 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1497729222?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

79 matching records · $1,435.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 79 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 79.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.6612/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057463805 CMS
E.R. Squibb & Sons, L.L.C. $17.9812/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016152375 CMS
Ironwood Pharmaceuticals, Inc $24.0012/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045571501 CMS
PFIZER INC. $15.3012/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050208233 CMS
ABBVIE INC. $9.9112/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537103 CMS
ABBVIE INC. $19.2612/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537101 CMS
ABBVIE INC. $0.9912/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537099 CMS
Astellas Pharma US Inc $19.7311/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034696751 CMS
ABBVIE INC. $16.1111/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537097 CMS
PFIZER INC. $16.2911/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049688693 CMS
Lilly USA, LLC $15.5011/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032204721 CMS
Xeris Pharmaceuticals, Inc. $21.3111/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056511165 CMS
ABBVIE INC. $31.8711/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537095 CMS
Novo Nordisk Inc $15.9611/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000879965 CMS
ABBVIE INC. $21.4310/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537091 CMS
ABBVIE INC. $0.7910/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537093 CMS
Novo Nordisk Inc $12.7410/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000879907 CMS
ABBVIE INC. $32.5410/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537087 CMS
ABBVIE INC. $17.8610/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537089 CMS
ABBVIE INC. $16.1109/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537085 CMS
ABBVIE INC. $7.6709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537083 CMS
Lilly USA, LLC $14.5009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032148251 CMS
Lundbeck LLC $15.6809/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032248553 CMS
Esperion Therapeutics, Inc. $20.4708/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050739923 CMS
ABBVIE INC. $13.9108/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537081 CMS
Abbott Laboratories $22.7908/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018757179 CMS
PFIZER INC. $113.2008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050298049 CMS
E.R. Squibb & Sons, L.L.C. $15.1008/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016152245 CMS
Amgen Inc. $16.6408/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020687809 CMS
AstraZeneca Pharmaceuticals LP $20.6407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011445483 CMS
Astellas Pharma US Inc $23.2107/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034293363 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.9007/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997005597 CMS
Lilly USA, LLC $14.0007/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032230967 CMS
Novo Nordisk Inc $15.0507/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000879950 CMS
PFIZER INC. $3.8407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049819349 CMS
ABBVIE INC. $15.7407/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537079 CMS
Ironwood Pharmaceuticals, Inc $24.1606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045584023 CMS
Xeris Pharmaceuticals, Inc. $19.6506/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056511173 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.4406/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000171025 CMS
Dynavax Technologies Corporation $12.1206/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 985818653 CMS
Azurity Pharmaceuticals, Inc. $18.4306/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988981201 CMS
E.R. Squibb & Sons, L.L.C. $15.1006/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016152173 CMS
ABBVIE INC. $15.3405/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997537077 CMS
Amgen Inc. $18.6705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020166039 CMS
Lilly USA, LLC $13.5505/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032280501 CMS
Astellas Pharma US Inc $23.2705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034110553 CMS
Amgen Inc. $13.6905/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020166047 CMS
Exact Sciences Corporation $16.8205/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026643925 CMS
Novo Nordisk Inc $14.9505/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000879935 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.4005/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000151537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,522.39 107
PY2020 $879.52 54
PY2021 $1,902.24 117
PY2022 $1,778.35 103
PY2023 $1,435.31 79
PY2024 $1,667.64 89
PY2025 $975.53 53

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $3,604.05 3
PY2020 Principal investigator $85,287.08 28
PY2019 Principal investigator $244,596.18 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $756.50 12/31/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241713
Principal investigator 1 Allergan, Inc. $150.00 12/31/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314435
Principal investigator 1 Allergan, Inc. $2,204.95 12/15/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241711
Principal investigator 1 Allergan, Inc. $552.00 12/08/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721311065
Principal investigator 1 Allergan, Inc. $1,928.50 11/16/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241703
Principal investigator 1 Allergan, Inc. $3,505.50 10/14/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241701
Principal investigator 1 Allergan, Inc. $850.00 09/21/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241699
Principal investigator 1 Allergan, Inc. $3,857.00 09/15/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241697
Principal investigator 1 Allergan, Inc. $3,480.65 08/31/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721294043
Principal investigator 1 Allergan, Inc. $276.00 08/21/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721293105
Principal investigator 1 Allergan, Inc. $4,211.50 08/18/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721290797
Principal investigator 1 Allergan, Inc. $3,086.55 08/13/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241691
Principal investigator 1 Allergan, Inc. $2,138.75 08/10/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721289033
Principal investigator 1 Allergan, Inc. $356.00 07/30/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721287751
Principal investigator 1 Allergan, Inc. $4,562.85 07/16/2020 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721241687
Principal investigator 1 Allergan, Inc. $200.00 06/16/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721279927
Principal investigator 1 Allergan, Inc. $3,958.65 06/16/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721280317
Principal investigator 1 Allergan, Inc. $4,235.10 05/13/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721274861
Principal investigator 1 Allergan, Inc. $660.00 05/12/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH INCORPORATED
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721274385
Principal investigator 1 Allergan, Inc. $25.26 05/04/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721273619
Principal investigator 1 Allergan, Inc. $9,391.70 04/14/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721270087
Principal investigator 1 Allergan, Inc. $2,406.35 03/19/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721266107
Principal investigator 1 Allergan, Inc. $10,504.15 03/13/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721263913
Principal investigator 1 Allergan, Inc. $5,965.05 02/24/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721259029
Principal investigator 1 Allergan, Inc. $4,450.75 02/13/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721256973
Principal investigator 1 Allergan, Inc. $5,315.25 01/22/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721249711
Principal investigator 1 Allergan, Inc. $6,039.15 01/15/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721248069
Principal investigator 1 Allergan, Inc. $218.92 01/08/2020 Non-covered Recipient Entity
OHIO CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721245611